The following video is from Wednesday's MarketFoolery podcast in which host Chris Hill and analysts Charly Travers and Jason Moser discuss the top business and investing stories.
In this segment, Biogen (NASDAQ:BIIB) had partnered with Elan (UNKNOWN:ELN.DL2) on a drug to treat multiple sclerosis. This morning, Biogen bought Elan's stake in the drug for $3.25 billion plus future royalties. While shares of Elan fell on the news, shares of Biogen were up. Our analysts discuss what the deal means for investors.
The relevant video segment can be found between 10:11 and 13:33.